Liver-specific lipoprotein (LSP) is a macromolecular lipid-related complex composed of more than 20 subunits with a molecular weight of >2×107 and containing various phospholipids (including cephalin, neurophospholipid, egg). Phospholipids and lysolecithin, etc.), cholesterol, fatty acids and triacylglycerols. It is located on the plasma membrane of liver cells, most of which are organ-specific and partly liver-specific. The LSP antigen has a non-specific antigenic determinant, and the antigenicity between human and rabbit is more similar between liver and kidney. Therefore, when preparing LSP antigen, rabbit liver can be used instead of human liver; in detecting anti-LSP antibody, mutual interference of kidney disease should be considered. Since LSP may be the target antigen for immunopathological responses in vivo, anti-LSP can kill autologous hepatocytes by antibody-dependent cell-mediated cytotoxicity (ADCC). It is believed that this may be the main cause of persistent damage to liver cells in the body.

Basic Information

Specialist classification: Digestive examination classification: immune examination

Applicable gender: whether men and women apply fasting: not fasting

Analysis results:

Below normal:

Normal value:

Above normal:

Normal human serum LSP antibody is negative.

Anti-LSP antibodies are mainly found in patients with acute viral hepatitis, chronic active hepatitis, chronic persistent hepatitis and cirrhosis.

Tips: The ratio of the absorbance (A) ratio (P/N) of the serum to the negative control to be tested is normal.

Normal human serum LSP antibody is negative.

Clinical significance

(1) Anti-LSP antibodies are mainly found in patients with acute viral hepatitis, chronic active hepatitis, chronic persistent hepatitis and cirrhosis, and are parallel with the degree of liver function damage in such patients. In chronic kidney disease, some cross-reactions may occur and should be identified.

(2) The detection of anti-LSP-IgG is related to the severity of hepatitis type. The detection rate of chronic severe hepatitis is the highest. The slow-lived liver, acute liver and cirrhosis are the second, the slow-moving liver is the lowest, and the titer changes with the disease. Fluctuations, dynamic observations, can estimate changes in the condition.

(3) Anti-LSP-IgM is mainly found in severe hepatitis and acute hepatitis. It appears early and has a short duration and seems to be an early indicator of hepatocyte injury.

(4) Anti-LSP-IgA is mainly found in cases with long duration of autoimmune response, which is of certain significance for distinguishing acute fluctuations of acute hepatitis and chronic hepatitis.


(1) According to the survey of normal population, the mean of serum radioactivity (cpm) plus 2 standard deviation is the upper limit of normal (radioimmunoassay).

(2) The ratio of absorbance (A) of the test serum to the negative control (P/N) < 2.1 (ELISA method).

Inspection process

Same as radioimmunoassay.

Not suitable for the crowd

There are no taboos.

Adverse reactions and risks

There are no related complications and hazards.